A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Pevonedistat (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms PEVOLAM
Most Recent Events
- 17 Mar 2025 Planned End Date changed from 30 Jun 2023 to 30 Jun 2025.
- 16 Jun 2024 Status changed to discontinued, according to Results presented at the 29th Congress of the European Haematology Association
- 02 Feb 2024 This trial has been Completed in Portugal, According to European Clinical Trials Database record.